ACRO | CD19:B細胞惡性腫瘤的有效治療標的

ACRO | CD19:B細胞惡性腫瘤的有效治療標的

2020.06.04

 【 CD19:B細胞惡性腫瘤的有效治療標的】

 CD19a validated therapeutic target for B-cell malignancies 


 

Product Features

 Biotinylated, fluorescent-labeled and unconjugated CD19 are available.

 High bioactivity verified by FACS, SPR and ELISA with protocol offered for free.

 Suitable for detection of anti-CD19 CAR expression and antibody drug screening.

 

 

 

Detection of Anti-CD19 CAR Expression by FACS
1e6 of the anti-CD19 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human CD19 (20-291), His Tag (Cat. No. CD9-HP2H3). PE Streptavidin was used as negative control (QC tested)

Protocol >>>

 

High Affinity Verified by SPR

Biotinylated Human CD19 (20-291), His,Avitag (Cat. No. CD9-H82E9) captured on Biotin CAP – Series S sensor Chip can bind FMC63 MAb (mouse lgG2a) with an affinity constant of 0.255 nM as determined in a SPR assay (Biacore 8K) (QC tested)

Protocol >>>

 

 

 

back-Top
open-line

LINE 線上諮詢

亞旭-LINE-QRcode

掃瞄或手機直接點擊條碼

error: Content is protected !!